Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15389825 | 0.89 | BACE1 (0.42) | IDO1BACE1DCPS | |
| SCHEMBL4033343 | 0.84 | BACE1 (0.40) | BACE1 | |
| SCHEMBL5467148 | 0.83 | BACE1 (0.39) | BACE1TAAR1ALDH1A1 | |
| SCHEMBL17094641 | 0.80 | BACE1 (0.33) | IDO1BACE1GAAMEN1KMT2A | |
| SCHEMBL20189141 | 0.80 | IDO1 (0.44) | IDO1BACE1GAADCPSTAAR1 | |
| SCHEMBL5462578 | 0.79 | IDO1 (0.45) | IDO1BACE1 | |
| SCHEMBL4680269 | 0.79 | BACE1 (0.42) | IDO1BACE1GAAMEN1KMT2A | |
| SCHEMBL23831781 | 0.78 | ALDH1A1 (0.38) | IDO1GAAKMT2ATAAR1ALDH1A1 | |
| SCHEMBL3940682 | 0.77 | BACE1 (0.44) | IDO1BACE1ALDH1A1 | |
| SCHEMBL4039599 | 0.77 | BACE1 (0.43) | BACE1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | IDO1 2775/4885BACE1 4411/4885GAA 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.